Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 327

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Colon cancer+1

Not recruiting

Study on the Impact of DPYD Gene Test on the Safety and Efficacy of Fluorouracil, Capecitabine, and Tegafur in Finnish Patients with Breast or Colon Cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:HUS-Yhtymae

Hepatocellular carcinoma

Not recruiting

Study on the Effectiveness and Safety of Nofazinlimab and Lenvatinib for Patients with Advanced Liver Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Cstone Pharmaceuticals (Suzhou) Co. Ltd.

Bone marrow disorder+1

Not recruiting

Study on the Effectiveness and Safety of Luspatercept for Patients with Lower-Risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept
  • Sponsor:GWT-Tud GmbH

Neoplasm malignant

Not recruiting

Study of Metronomic Oral Vinorelbine with Durvalumab and Tremelimumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Unicancer

Myelodysplastic syndrome

Not recruiting

Study on the Safety and Effectiveness of Azacitidine and Venetoclax for Untreated Higher-Risk Myelodysplastic Syndromes Not Eligible for Transplant

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Groupe Francophone Des Myelodysplasies

Chronic lymphocytic leukaemia

Not recruiting

Study on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hormone-refractory prostate cancer

Not recruiting

Study of ODM-208 (opevesostat) safety and effectiveness in patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:ODM-208
  • Sponsor:Orion Corporation

Non-small cell lung cancer

Not recruiting

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Myelofibrosis+1

Not recruiting

Study of Pacritinib for Patients with Severe Thrombocytopenia in Myelofibrosis Conditions

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Sobi Inc.

Mantle cell lymphoma stage II+2

Not recruiting

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ibrutinib
  • Sponsor:Klinikum der Universitaet Muenchen AöR

Non-small cell lung cancer

Not recruiting

Study on Durvalumab for Patients with Completely Removed Non-Small Cell Lung Cancer

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Clinipace Global Limited

Skin cancer+1

Not recruiting

Study on Balstilimab for Patients with Advanced Non-Melanoma Skin Cancers

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.